NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 123 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $980,000 | -29.0% | 74,953 | -30.4% | 0.26% | -29.8% |
| Q2 2022 | $1,380,000 | -16.0% | 107,653 | 0.0% | 0.38% | -12.1% |
| Q1 2022 | $1,642,000 | +15.2% | 107,653 | +33.8% | 0.43% | +19.6% |
| Q4 2021 | $1,425,000 | +3.6% | 80,485 | +22.9% | 0.36% | -1.9% |
| Q3 2021 | $1,376,000 | +129.0% | 65,485 | +114.7% | 0.36% | +189.7% |
| Q2 2021 | $601,000 | +106.5% | 30,502 | +205.0% | 0.13% | +82.6% |
| Q1 2021 | $291,000 | +216.3% | 10,000 | +59.6% | 0.07% | +97.1% |
| Q2 2019 | $92,000 | – | 6,265 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |